GlassScriptPhysician profile
Leonid Chernyak
NPI 1457507469
$2,672.98
in general payments reported to CMS, 2019-2025
32 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $236 · 2021: $593 · 2022: $495 · 2023: $537 · 2024: $328 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $489.43 | 2020-2025 | Ztlido |
| Medtronic, INC. | $378.62 | 2022-2023 | Intellis Adaptivestim |
| Abbvie INC. | $248.81 | 2022-2025 | Ubrelvy, Qulipta |
| Abbott Laboratories | $237.32 | 2021-2024 | Proclaim |
| Eisai INC. | $137.42 | 2024-2025 | |
| Mml US, INC. | $112.86 | 2023 | Reactiv8 |
| Fisher & Paykel Healthcare Limited | $105.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $103.01 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.08 | 2019-2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $73.33 | 2022 | |
| Pfizer INC. | $64.04 | 2023 | |
| Collegium Pharmaceutical, INC. | $56.70 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.60 | 2021 | |
| Depuy Synthes Sales INC. | $44.78 | 2019-2024 | Orthovisc |
| Si-Bone, INC. | $37.81 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $35.79 | 2021 | |
| Nevro Corp. | $34.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.12 | 2019 | |
| Painteq LLC | $31.82 | 2021 | |
| Almatica Pharma LLC | $28.57 | 2021 | |
| Medtronic USA, INC. | $27.97 | 2020 | |
| Merck Sharp & Dohme LLC | $27.78 | 2023 | Bridion |
| Indivior INC. | $26.23 | 2025 | Sublocade |
| Stimwave Technologies Incorporated | $25.42 | 2022 | |
| Baudax Bio INC. | $24.99 | 2020 | |
| Redhill Biopharma INC. | $22.37 | 2022 | |
| Amgen INC. | $21.80 | 2024 | Uplizna |
| Hikma Pharmaceuticals USA | $21.09 | 2022 | |
| Alkermes, INC. | $21.00 | 2019 | |
| Horizon Therapeutics Plc | $19.68 | 2021 | |
| Virtus Pharmaceuticals LLC | $18.94 | 2021 | |
| Glaxosmithkline, LLC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Chernyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.